BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baji P, Gulácsi L, Brodszky V, Végh Z, Danese S, Irving PM, Peyrin-Biroulet L, Schreiber S, Rencz F, Lakatos PL, Péntek M. Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe. United European Gastroenterol J 2018;6:310-21. [PMID: 29511561 DOI: 10.1177/2050640617708952] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Bouhnik Y, Atreya R, Casey D, Górecki M, Baik D, Yoon SW, Kwon TS, Jang M. Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment. Inflamm Bowel Dis 2022:izac160. [PMID: 35942647 DOI: 10.1093/ibd/izac160] [Reference Citation Analysis]
2 Anisdahl K, Svatun Lirhus S, Medhus AW, Moum B, Melberg HO, Høivik ML. First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study. Scand J Gastroenterol 2021;:1-6. [PMID: 34320885 DOI: 10.1080/00365521.2021.1955147] [Reference Citation Analysis]
3 Scott FI, Luo M, Shah Y, Lasch K, Vajravelu RK, Mamtani R, Fennimore B, Gerich ME, Lewis JD. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. J Crohns Colitis 2020;14:575-87. [PMID: 31901085 DOI: 10.1093/ecco-jcc/jjz212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Santos-Neto JF, Oliveira FO, Hodel KVS, Fonseca LMS, Badaró R, Machado BAS. Technological Advancements in Monoclonal Antibodies. ScientificWorldJournal 2021;2021:6663708. [PMID: 33628140 DOI: 10.1155/2021/6663708] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Dutta B, Huys I, Vulto AG, Simoens S. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price! BioDrugs 2020;34:159-70. [PMID: 31792843 DOI: 10.1007/s40259-019-00395-w] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 25.0] [Reference Citation Analysis]
6 Luchristt D, Geynisman-Tan J, Mueller MG, Kenton K. Cost-effectiveness Analysis of Universal Cystoscopy at the Time of Benign Laparoscopic Hysterectomy. J Minim Invasive Gynecol 2021;28:1470-83. [PMID: 33310171 DOI: 10.1016/j.jmig.2020.12.004] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Talathi S, Baig KRKK. Biosimilars in inflammatory bowel disease. J Dig Dis 2020;21:610-20. [PMID: 32920972 DOI: 10.1111/1751-2980.12940] [Reference Citation Analysis]
8 AlRuthia Y, Almadi M, Aljebreen A, Azzam N, Alsharif W, Alrasheed H, Almuaythir G, Saeed M, HajkhderMullaissa B, Alharbi O. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia. J Med Econ 2020;23:1102-10. [PMID: 32619388 DOI: 10.1080/13696998.2020.1791889] [Reference Citation Analysis]
9 Park SH, Park JC, Lukas M, Kolar M, Loftus EV. Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases. Intest Res 2020;18:34-44. [PMID: 32013313 DOI: 10.5217/ir.2019.09147] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Broide E, Eindor-abarbanel A, Naftali T, Shirin H, Shalem T, Richter V, Matalon S, Leshno M. Early Surgery Versus Biologic Therapy in Limited Nonstricturing Ileocecal Crohn’s Disease—A Decision-making Analysis. Inflammatory Bowel Diseases 2020;26:1648-57. [DOI: 10.1093/ibd/izz282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Drenth JP. United European Gastroenterology Journal and UEG Week. United European Gastroenterol J 2019;7:995-6. [PMID: 31662856 DOI: 10.1177/2050640619874266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Holko P, Kawalec P, Pilc A. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist. Pharmacoeconomics 2018;36:853-65. [PMID: 29667146 DOI: 10.1007/s40273-018-0653-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
13 Schütz L, Radke M, Menzel S, Däbritz J. Long-term implications of structured transition of adolescents with inflammatory bowel disease into adult health care: a retrospective study. BMC Gastroenterol 2019;19:128. [PMID: 31324228 DOI: 10.1186/s12876-019-1046-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
14 Gonczi L, Ilias A, Kurti Z, Lakatos PL. Biosimilars in IBD: Will it Benefit to Patients, Physicians or the Health Care System? CPD 2019;25:13-8. [DOI: 10.2174/1381612825666190312112900] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Rencz F, Stalmeier PFM, Péntek M, Brodszky V, Ruzsa G, Gönczi L, Palatka K, Herszényi L, Schäfer E, Banai J, Rutka M, Gulácsi L, Lakatos PL. Patient and general population values for luminal and perianal fistulising Crohn's disease health states. Eur J Health Econ 2019;20:91-100. [PMID: 31102158 DOI: 10.1007/s10198-019-01065-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Sahnan K, Tozer PJ, Adegbola SO, Lee MJ, Heywood N, McNair AGK, Hind D, Yassin N, Lobo AJ, Brown SR, Sebastian S, Phillips RKS, Lung PFC, Faiz OD, Crook K, Blackwell S, Verjee A, Hart AL, Fearnhead NS; ENiGMA collaborators. Developing a core outcome set for fistulising perianal Crohn's disease. Gut 2019;68:226-38. [PMID: 29437911 DOI: 10.1136/gutjnl-2017-315503] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 15.3] [Reference Citation Analysis]
17 Vasudevan A, Gibson PR, Van Langenberg DR. Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2019;25:1462-73. [DOI: 10.1093/ibd/izy399] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
18 Rencz F, Lakatos PL, Gulácsi L, Brodszky V, Kürti Z, Lovas S, Banai J, Herszényi L, Cserni T, Molnár T, Péntek M, Palatka K. Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease. Qual Life Res 2019;28:141-52. [PMID: 30225788 DOI: 10.1007/s11136-018-2003-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
19 Kurti Z, Gonczi L, Lakatos PL. Progress with infliximab biosimilars for inflammatory bowel disease. Expert Opin Biol Ther 2018;18:633-40. [PMID: 29688797 DOI: 10.1080/14712598.2018.1469620] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]